刺激性咳嗽症候群治疗市场－全球产业规模、份额、趋势、机会及预测（依药物类别、通路、地区及竞争格局划分，2021-2031年）

全球咳嗽刺激症候群治疗市场预计将从 2025 年的 45.4 亿美元成长到 2031 年的 63.4 亿美元，复合年增长率为 5.72%。

咳嗽过敏症候群 (CHS) 是一种临床疾病，其特征是由于感觉神经过敏，导致低强度化学、热或机械刺激诱发慢性咳嗽，且即使在原发性疾病得到治疗后，咳嗽症状也常常持续存在。人口老化和呼吸系统疾病盛行率的上升是推动该市场成长要素，这使得人们迫切需要有效治疗现有镇咳药物无法解决的难治性病例。庞大的患者群也支撑着这庞大的市场需求。根据欧洲呼吸学会 (ERS) 2024 年发布的报告，慢性咳嗽影响着全球约 5-10% 的成年人，这表明新型神经调节药物存在巨大的未满足需求。

然而，新兴治疗方法的安全性问题引发了严格的监管壁垒，严重阻碍了市场扩张。由于担心味觉障碍等副作用，卫生监管机构对新药候选产品，特别是P2X3拮抗剂，制定了严格的标准。这种严格的审查需要大量的临床检验，导致关键地区的产品核可延迟，并成为新治疗方法快速商业化和全球整个行业发展的主要障碍。

市场驱动因素

新型P2X3受体拮抗剂的问世是推动全球咳嗽过敏症候群治疗市场变革的重要催化剂。这些药物针对气道感觉神经元上的P2X3受体，阻断驱动高敏感性咳嗽反射的ATP讯号路径。与传统的神经抑制剂相比，此药物的作用机转更为特异性，后者主要针对神经元敏化的生理根源。这些候选药物临床疗效的证实正在提振市场信心。例如，2025年3月发表于《美国呼吸与危重症医学杂誌》的报告显示，P2X3拮抗剂camripixant的IIb期研究显示，在安慰剂校正的以金额为准上，24小时咳嗽频率降低了34%。这种标靶定向是关键驱动因素，可望为此前缺乏有效治疗方案的患者带来更好的治疗效果。

同时，针对多种神经系统标靶的强大临床研发管线以及不断增长的药物研发投入正在推动市场发展。为了应对疾病的异质性，各公司正在探索P2X3受体抑制以外的机制，例如鸦片受体促效剂。根据FirstWord Pharma于2025年3月报道，在IIa期RIVER试验中，试验性药物Hadubio在校正安慰剂后，使咳嗽频率显着降低了57%。鑑于患者负担沉重，这种积极的创新至关重要。 2025年7月发表于ERJ Open Research的一项研究表明，高达27.9%的慢性咳嗽患者可能患有难治性或不明原因的慢性咳嗽，这凸显了该行业向精准医疗的重大转变。

市场挑战

全球咳嗽过敏症候群治疗市场的成长受到新治疗方法安全性方面严格监管障碍的显着限制。由于有通报某些药物有味觉障碍等不良反应风险，卫生监管机构对新药候选药物，尤其是涉及P2X3受体拮抗剂的药物，制定了严格的标准。这种严格的审查需要广泛的临床检验，导致研发週期延长，产品核可严重滞后，直接阻碍了新治疗方法的快速商业化。

这些监管瓶颈严重阻碍了满足对标准治疗无效患者的需求，限制了市场参与企业的收入潜力。大量难治性病例因延误而未能解决，凸显了错失良机的巨大影响。欧洲呼吸学会 (ERS) 2024 年的一项调查发现，在评估族群中，高达 27.9% 的慢性咳嗽患者被归类为潜在难治性或病因不明的慢性咳嗽。因此，无法迅速通过这些安全法规的审批，导致重要的神经调节药物上市延迟，从而有效地限制了全球市场的扩张。

市场趋势

人工智慧驱动的声学咳嗽监测技术的整合，从根本上改变了过敏性咳嗽症候群的治疗管理方式，将诊断和治疗追踪从患者主观记忆转变为客观、连续的数据分析。这项技术不仅提高了诊断准确性，还能够提供直接针对疾病行为因素的数位疗法。这些平台的临床效用正日益凸显。 2025年10月，Hyfe公司发表了一项重要研究成果，显示数位行为咳嗽抑制疗法可使病因不明的难治性慢性咳嗽患者的平均咳嗽频率降低41.8%。这些进展凸显了市场趋势，即医疗软体（SaMD）在药物治疗中发挥着不可或缺的补充作用，提供非侵入性措施来改善患者的生活品质。

同时，为应对慢性咳嗽病理的异质性，慢性咳嗽专科诊所的建立正在加速推进。这些诊所促进了包括物理治疗、语言治疗和精准表型分析在内的跨学科诊疗模式。这些专科中心对于对标准止咳治疗无效的患者进行分层，以及透过系统化的註册登记系统产生大规模的真实世界证据至关重要。这项基础设施的扩展体现在多项重要的泛欧措施。正如2025年9月《欧洲呼吸杂誌开放研究》所详述的，NEuroCOUGH慢性咳嗽註册登记计画启动，该计画在欧洲13个中心招募了2500名患者，旨在规范专科诊疗并改善新兴治疗方法的临床试验基础设施。这一趋势标誌着治疗路径正朝着更差异化和严谨的方向发展，确保新型治疗方法应用于最合适的患者群体。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球易激惹咳嗽症候群治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（镇咳药、吸入性皮质类固醇、短效β2促效剂、抗胆碱能药物、抗组织胺、质子帮浦阻断剂、其他）
  • 通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美易激惹咳嗽症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲易激惹咳嗽症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区易激惹咳嗽症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲过敏性咳嗽症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲易激惹咳嗽症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球易激惹咳嗽症候群治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Pfizer Inc.
• GlaxoSmithKline plc.
• Boehringer Ingelheim GmbH.
• AstraZeneca PLC.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Merck & Co. Inc.
• Vertex Pharmaceuticals Incorporated.
• Johnson & Johnson Consumer Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cough Hypersensitivity Syndrome Treatment Market is projected to grow from USD 4.54 Billion in 2025 to USD 6.34 Billion by 2031, expanding at a CAGR of 5.72%. Cough Hypersensitivity Syndrome (CHS) is characterized as a clinical condition where chronic coughing is triggered by low-level chemical, thermal, or mechanical stimuli due to sensory neuronal hypersensitivity, often persisting even after underlying comorbidities are treated. The market is primarily driven by an aging population and the increasing prevalence of respiratory disorders, which create a need for effective management of refractory cases that existing antitussives cannot resolve. This significant demand is supported by the scale of the affected demographic; the European Respiratory Society reported in 2024 that chronic cough affects approximately 5% to 10% of adults worldwide, indicating a substantial unmet medical need for new neuromodulators.

However, market expansion faces significant impediments due to stringent regulatory hurdles related to the safety profiles of emerging therapies. Health authorities have established rigorous standards for novel candidates, particularly P2X3 antagonists, because of concerns regarding adverse effects like taste disturbances. This intense scrutiny requires extensive clinical validation and has caused delays in product approvals within key regions, acting as a major barrier to the rapid commercialization of new treatments and the overall growth of the global sector.

Market Driver

The introduction of novel P2X3 receptor antagonists is a primary catalyst transforming the Global Cough Hypersensitivity Syndrome Treatment Market. These agents target P2X3 receptors on airway sensory neurons to block the ATP signaling pathway that drives the hypersensitive cough reflex, offering a highly specific mechanism compared to traditional central nervous system suppressants that addresses the physiological root of neuronal sensitization. Market confidence is being accelerated by the clinical validation of these candidates; for example, the American Journal of Respiratory and Critical Care Medicine reported in March 2025 that Phase IIb results for the P2X3 antagonist camlipixant showed a 34% placebo-adjusted reduction in 24-hour cough frequency. This targeted efficacy is a pivotal driver, promising better outcomes for patients who historically have had no effective options.

Concurrently, the market is propelled by a strong clinical pipeline and increasing pharmaceutical R&D investment focused on diverse neurological targets. To address the heterogeneous nature of the condition, companies are exploring mechanisms beyond P2X3 inhibition, such as opioid receptor agonists. As noted by FirstWord Pharma in March 2025, the investigational therapy Haduvio achieved a statistically significant 57% placebo-adjusted reduction in cough frequency in the Phase IIa RIVER trial. This aggressive innovation is crucial given the substantial patient burden; a July 2025 study in ERJ Open Research identified that up to 27.9% of the chronic cough population suffers from possible refractory or unexplained chronic cough, underscoring a major industry shift toward precision medicine.

Market Challenge

The growth of the Global Cough Hypersensitivity Syndrome Treatment Market is significantly restricted by stringent regulatory hurdles concerning the safety profiles of emerging therapies. Health authorities have mandated rigorous standards for novel candidates, especially P2X3 antagonists, due to documented risks of adverse effects such as taste disturbances. This intense scrutiny necessitates extensive clinical validation, leading to prolonged development timelines and substantial delays in product approvals, which directly hinders the rapid commercialization of new treatments.

These regulatory bottlenecks create a critical barrier to meeting the needs of patients who do not respond to standard care, thereby limiting the revenue potential for market participants. The magnitude of this missed opportunity is underscored by the prevalence of difficult-to-treat cases that remain unaddressed due to these delays. According to the European Respiratory Society in 2024, research indicated that up to 27.9% of individuals with chronic cough in assessed populations were classified as having possible refractory or unexplained chronic cough. Consequently, the inability to swiftly navigate these safety regulations stalls the introduction of vital neuromodulators, effectively capping the expansion of the global sector.

Market Trends

The integration of AI-driven acoustic cough monitoring is fundamentally reshaping the management of Cough Hypersensitivity Syndrome by shifting diagnosis and treatment efficacy tracking from subjective patient recall to objective, continuous data analysis. This technology not only improves diagnostic precision but also enables the delivery of digital therapeutics that directly address the behavioral components of the condition. The clinical utility of these platforms is becoming increasingly clear; in October 2025, Hyfe, Inc. reported that a pivotal study showed digital Behavioral Cough Suppression Therapy reduced average cough frequency by 41.8% in patients with refractory and unexplained chronic cough. Such advancements highlight a market trend where software-as-a-medical-device (SaMD) acts as an integral companion to pharmacological interventions, offering a non-invasive method to enhance patient quality of life.

Simultaneously, the establishment of specialized chronic cough clinics is gaining momentum as a structural response to the disease's heterogeneity, facilitating multidisciplinary care models that include physiotherapy, speech therapy, and precise phenotyping. These dedicated centers are essential for stratifying patients who fail standard antitussive therapy and for fostering large-scale real-world evidence generation through organized registries. This infrastructural expansion is exemplified by major pan-European initiatives; as detailed in the European Respiratory Journal Open Research in September 2025, the NEuroCOUGH Chronic Cough Registry was launched to recruit 2,500 patients across 13 European sites to standardize specialist care and improve the clinical trial infrastructure for emerging therapies. This trend signifies a move towards a more segmented and rigorous care pathway, ensuring that novel treatments are matched with the most suitable patient phenotypes.

Key Market Players

• Pfizer Inc.
• GlaxoSmithKline plc.
• Boehringer Ingelheim GmbH.
• AstraZeneca PLC.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Merck & Co. Inc.
• Vertex Pharmaceuticals Incorporated.
• Johnson & Johnson Consumer Inc.

Report Scope

In this report, the Global Cough Hypersensitivity Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cough Hypersensitivity Syndrome Treatment Market, By Drug Class

• Antitussive Agents
• Inhaled Corticosteroids
• Short Acting Beta-2 Agonists
• Anti-Cholinergics
• Antihistamines
• Proton Pump Inhibitors
• Others

Cough Hypersensitivity Syndrome Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cough Hypersensitivity Syndrome Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cough Hypersensitivity Syndrome Treatment Market.

Available Customizations:

Global Cough Hypersensitivity Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cough Hypersensitivity Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Antitussive Agents, Inhaled Corticosteroids, Short Acting Beta-2 Agonists, Anti-Cholinergics, Antihistamines, Proton Pump Inhibitors, Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Cough Hypersensitivity Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Cough Hypersensitivity Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. South America Cough Hypersensitivity Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cough Hypersensitivity Syndrome Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc.
• 15.3. Boehringer Ingelheim GmbH.
• 15.4. AstraZeneca PLC.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Novartis AG.
• 15.8. Merck & Co. Inc.
• 15.9. Vertex Pharmaceuticals Incorporated.
• 15.10. Johnson & Johnson Consumer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer